The treatment landscape for chronic obstructive pulmonary disease (COPD) continues to evolve with the introduction of therapies targeting novel inflammatory and bronchodilator pathways. Understanding these newer treatment options is becoming increasingly important when optimizing maintenance therapy for symptomatic patients. Here is a quick question on contemporary COPD management! (Scroll down to answer the question) ##Reference## Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283; PMCID: PMC10449067.## ##Disclaimer## The content provided…
